FDA
-
-
-
-
-
-
-
Pliant Therapeutics (PLRX) Reports Interim Phase 1 Data for PLN-101095
-
-
-
-
-
-
-
Pliant Therapeutics Inc. (PLRX) Announces Next Steps Following DSMB Recommendation on BEACON-IPF
-
-
-
-
-
-
-
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
-
-
-
-
-
-
-
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
-
-
-
-
-
-
-
Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

